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 2 
What does this study add to the existing literature and how will it influence 25 
future clinical practice? 26 
The management of patients with type B aortic dissection is complex. A number 27 
of cases series have been published to try to better understand these patients but 28 
they are limited by their small size. IRAD is a highly valuable resource but pools 29 
data from a number of centres across the world and is therefore limited by the 30 
heterogeneity of the data. This manuscript describes the findings of the largest 31 
single centre series published to date and provides new insights into the 32 
management of these complex patients.  33 
34 
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Abstract 35 
Objectives: To evaluate in patients with acute type B aortic dissection the results 36 
of medical and endovascular treatment in large single centre experience and to 37 
investigate the clinical and imaging features on presentation that relate to poor 38 
outcome. 39 
 40 
Design: Retrospective analysis of prospectively collected clinical and CT imaging 41 
data. 42 
 43 
Materials: 136 consecutive patients with acute type B aortic dissection were 44 
included in the study over an 11-year period.  45 
 46 
Methods: Characteristics of patients receiving endovascular (complicated) or 47 
medical treatment (uncomplicated) were compared. Kaplan Meier estimators 48 
were used to estimate cumulative overall survival and survival free of aortic 49 
events. Factors associated with overall and aortic event free survival were also 50 
explored using Cox-proportional hazards models.  51 
 52 
Results: The mean follow-up was 51 months (1-132), during which time 33 53 
deaths and 48 aortic events occurred. At one year and five years overall survival 54 
was 94.0% and 74.8% respectively and freedom from aortic events was 75.6% 55 
and 58.7%. There was no difference in all cause survival and aortic event-free 56 
survival at one and five years between the patients treated endovascularly and 57 
those receiving medical treatment alone. Risk analysis for aortic events 58 
demonstrated the maximum size of the proximal entry tear, the maximum 59 
 4 
thoracic aortic diameter and the thoracic aortic false lumen maximum diameter 60 
to have a significant effect on the incidence of aortic events.  61 
 62 
Conclusions: Active management of patients with type B aortic dissection results 63 
in good long-term survival even in the presence of features traditionally 64 
associated with adverse outcomes. All patients require close lifetime surveillance 65 
as aortic events, even after endografting, continue to occur during follow-up.  66 
 67 
Keywords: Survival, risk analysis, aortic dissection 68 
69 
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Introduction 70 
Type B aortic dissection is a complex clinical entity. In the presence of 71 
complications such as rupture and end-organ ischaemia urgent endovascular 72 
intervention is required.(1) Uncomplicated cases are currently treated medically, 73 
with active management of blood pressure, to try to prevent complications 74 
during follow-up such as extension of the dissection, aneurysm formation, and 75 
rupture. 76 
 77 
Previous series have however demonstrated that even in the presence of good 78 
blood pressure control survival is poor, with only 50-70% of patients alive at 5 79 
years, with a delayed expansion of the false lumen in 20-50% of patients at 4-80 
years.(2-4) Many of the deaths that occur during follow up are aortic related.  81 
 82 
A number of groups, largely in Asian patient populations, have tried to identify 83 
clinical and anatomical features that could be measured on presentation and be 84 
used to predict outcome, and therefore identify patients at high risk of aortic 85 
events and death during follow-up.(5) The majority of these studies have been 86 
performed in small series (<40 patients), with results from some studies 87 
contradicting the results of others and so currently there is no reliable method to 88 
identify these high-risk patients. 89 
 90 
There is growing interest in early endovascular treatment of patients with type B 91 
aortic dissection to prevent aortic events during follow up and therefore improve 92 
survival. It is hoped that treating patients early will produce the best outcomes 93 
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because the aorta has plasticity and is therefore likely to undergo positive aortic 94 
remodelling following stent graft insertion.(6)  95 
 96 
We have an 11-year experience in the management of patients with type B aortic 97 
dissection using best medical treatment for uncomplicated and thoracic 98 
endovascular repair (TEVAR) for complicated dissection. The aim of this study 99 
was to evaluate the results that can be achieved with medical and endovascular 100 
treatment in these patients in a large single centre experience and to investigate 101 
the features on presentation that relate to a poor outcome.    102 
 103 
104 
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Materials and methods 105 
Study design 106 
136 consecutive patients with acute type B aortic dissection were included in the 107 
study over an eleven-year period. All patients were managed in a high 108 
dependency setting with medical management implemented by medical 109 
specialists trained in the management of hypertension. Patients that presented 110 
with evidence of aortic rupture, end-organ ischaemia or on-going pain despite 111 
good blood pressure control were defined as complicated and treated 112 
endovascularly, those without these features were treated with best medical 113 
therapy. Patients were excluded if the aortic dissection was secondary to trauma 114 
or iatrogenic injury. Patients were categorised into groups based upon their 115 
treatment. All patients were followed up by both a cardiologist with a special 116 
interest in aortic dissection and hypertension and a vascular surgeon.  117 
 118 
Endovascular repair 119 
Thoracic endovascular repair was performed in a standard operating room with 120 
mobile C-arm or in a hybrid operating room using percutaneous vascular access 121 
whenever possible. Left common carotid to left subclavian artery (LSCA) bypass 122 
or transposition was considered if the stent graft covered the origin of the LSCA. 123 
Absolute indications for LSCA revascularisation were: left internal mammary 124 
artery bypass graft; diminutive, atretic or absent right vertebral artery; left arm 125 
arterio-venous fistula for haemodialysis; patent left axillo-femoral bypass graft; 126 
and dominant left vertebral artery. These procedures were performed prior to, 127 
or at the time of the TEVAR procedure, depending upon the level of urgency of 128 
the case. The stent graft was sized to the proximal un-dissected aorta with 10-129 
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15% oversizing. In cases of rupture the stent grafts were positioned to cover the 130 
thoracic aorta from proximal to the primary entry tear to the level of the coeliac 131 
trunk. 132 
 133 
Best medical therapy 134 
Best medical therapy was implemented using a combination of antihypertensive 135 
medications. Our preferred stepwise approach was as follows: β –blocker, ACE-136 
inhibitor, calcium channel blocker then diuretics with a final option of alpha-137 
receptor blocker and/or a centrally acting antihypertensive agent. Blood 138 
pressure control was based on the European Society of Cardiology guidelines 139 
with a target blood pressure of below 135/80 mmHg.  140 
 141 
Image analysis 142 
Computed tomography (CT) angiographic images of the aorta were acquired on 143 
presentation and during follow-up using an iodinated contrast agent. All images 144 
were analysed on a dedicated Aquarius iNtuition workstation (TeraRecon, Foster 145 
City, Calif) by two vascular surgeons experienced in the endograft planning for 146 
aortic dissection. The arterial phase images, reconstructed to ≤1mm, were 147 
evaluated and the number of entry tears, the size of the primary entry tear, the 148 
length of the dissection, the amount of thrombosis in the false lumen and the 149 
dimensions of the aorta and the true and false lumen were recorded. The true 150 
lumen was identified as the lumen continuous with the proximal undissected 151 
aorta. The maximum diameter of the primary entry tear was measured using 152 
multi-planar reformatted (MPR) images, false lumen thrombosis was assumed to 153 
be present when there was absence of contrast enhancement and volumes were 154 
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calculated by segmentation and summation over contiguous slices.  The 155 
following were recorded: i. the maximum aortic diameter; ii. the true and false 156 
lumen diameters in the thoracic aorta at the level of the inferior pulmonary vein; 157 
and iii. the true and false lumen diameters in the abdominal section at the level of 158 
the IMA (or at the mid-point of the third lumbar vertebra if the IMA could not be 159 
seen). All diameter measurements were made using MPR images to ensure 160 
precision.   161 
 162 
Statistical analysis 163 
Characteristics of patients receiving endovascular or medical treatment alone 164 
were summarised within each group and compared using Mann-Whitney, chi-165 
squared or fisher’s exact test, as appropriate. Kaplan Meier estimators were used 166 
to estimate cumulative overall survival and survival free of aortic events with 167 
95% confidence intervals at one and 5 years after admission. Aortic events were 168 
rupture, extension of the dissection and further intervention. Kaplan Meier 169 
estimators were also calculated within subgroups of patients. Factors associated 170 
with overall and aortic event free survival were also explored using Cox-171 
proportional hazards models. Due to small sample sizes, for categorical data the 172 
estimation of one and five year survival rates and the application of Cox models 173 
were restricted to variables with at least 20% of patients in each subgroup. 174 
Where Cox models indicated a statistically significant association Kaplan Meier 175 
curves were plotted. For continuous variables cut points were selected that 176 
divided the data into three approximately equal sized groups and Kaplan Meier 177 
curves estimates for each of these groups. Analysis was conducted using STATA 178 
13MP and p-values <0.05 considered statistically significant.  179 
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Results 180 
Baseline characteristics 181 
The baseline characteristics for the 136 patients are summarised in Table 1. The 182 
average age at admission was 61.7 years and the majority of the cohort were 183 
male (77.2%). Seventy-one per cent of the cohort had hypertension, 9.6% had 184 
diabetes and 5.9% had known connective tissue disease. Sixty-four patients 185 
presented with complications and were treated endovascularly. The most 186 
common complication was end-organ ischaemia (n=45); aortic rupture was 187 
present in 17 cases and 5 patients were treated for on-going pain despite good 188 
blood pressure control. Three patients had both rupture and end-organ 189 
ischaemia. The patients that were treated endovascularly were significantly 190 
younger than the patients treated with medical treatment alone (mean age 58.5 191 
versus 64.5 years). β –blocker was the most commonly used antihypertensive 192 
agent to treat aortic dissection in both treatment groups [Suppl. table 1].  193 
The incidence of in-hospital events were: acute coronary syndrome 3.7% 194 
(endovascular n=3, medical treatment alone n=2), neurological complications 195 
7.4% (endovascular n=7, medical treatment alone n=3), dialysis 2.9% 196 
(endovascular n=3, medical treatment alone n=1), pulmonary infection 11.8% 197 
(endovascular n=11, medical treatment alone n=5).  198 
 199 
Anatomical features 200 
The anatomical features of the cohort are shown in Table 2 and Suppl. Table 2. At 201 
presentation the maximum aortic diameter was greater in the endovascularly 202 
treated group compared with the group treated with medical treatment alone. In 203 
both groups the dissection tended to involve both the thoracic and abdominal 204 
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aorta (endovascular group 93%, medical treatment only group 81.7%). In the 205 
endovascularly treated group the true lumen tended to be smaller than the false 206 
lumen, whereas in the group that received medical treatment only the true 207 
lumen was greater than the false lumen. In both treatment groups a large 208 
proportion of the patients had a patent false lumen and there was no difference 209 
in the number of entry tears. The size of the largest entry tear was significantly 210 
greater in the endovascular treatment group.  211 
At 2-years follow-up there was an average increase in the true lumen diameter of 212 
the thoracic aorta of 8mm in the endovascular treatment group with no 213 
corresponding increase in the true lumen diameter of the abdominal segment in 214 
this group. The majority of the patients in the medically treated group had 215 
partial (51.7%) or complete (34.5%) thoracic aortic false lumen thrombosis 216 
whereas in the endovascularly treated group approximately one third of patients 217 
had patency of the false lumen. At 5-years the average size of the false lumen in 218 
the endovascularly treated group had increased compared to the 2-year data and 219 
only 27.3% of patients had complete thrombosis of the thoracic aortic false 220 
lumen following endovascular treatment.   221 
 222 
Survival analysis 223 
The mean follow up in the cohort was 51 (1-132) months; thirty-three deaths, 8 224 
aortic-related, 10 cardiac, 10 cancer-related and 5 other occurred, and 48 aortic 225 
events were recorded. The 30-day all cause survival and aortic event-free 226 
survival were 98.5% (94.3-99.6%) and 94.8% (89.4-97.5%) respectively. 227 
Cumulative survival was 94.0% (95% CI 88.4 - 97.0%) at one year and 74.8% 228 
(64.5-82.5%) at five years [Figure 1]. The aortic event-free survival at one year 229 
 12 
and at five years was 75.6% (67.3-82.1%) and 58.7% (48.1-67.8%) respectively 230 
[Figure 2].  231 
There was no difference in all cause survival at one and five years between the 232 
patients treated endovascularly and those receiving medical treatment alone 233 
(HR=0.99 (0.49-2.02), p=0.996). There was no difference in aortic event-free 234 
survival at one and five years between the patients treated endovascularly and 235 
those receiving medical treatment alone (HR=1.33 (0.78-2.34), p=0.329).   236 
 237 
Factors associated with overall and aortic event free survival  238 
Patient characteristics, cardiovascular risk factors and imaging features, and 239 
their association with all-cause survival, are summarised in supplementary 240 
tables 3, 4 and 5 respectively. Age was significantly associated with all cause 241 
survival with an increase in hazard of death of 26% for every 5 years increase in 242 
age (HR=1.26 (1.08-1.46), p=0.003) [Suppl. Figure 1]. There was no association 243 
between cardiovascular parameters, CRP, eGFR and the amount of hypertensive 244 
medication on admission and all cause mortality. There was an inverse 245 
relationship between the amount of anti-hypertensive medication on discharge 246 
and survival. An increase of one drug in the number of antihypertensive 247 
medications prescribed resulted in a decrease in hazard of death of 32% 248 
(HR=0.68 (0.53-0.88), p=0.013) [Suppl. Figure 2]. Aortic event-free survival data 249 
is presented in supplementary tables 6, 7 and 8. Taller patients were more likely 250 
to experience an aortic event during follow up; with a one centimetre increase in 251 
height associated with an increase in the hazard of experiencing an aortic event 252 
of 5% (HR=1.04 (1.01-1.05), p=0.005) [Suppl. Figure 3]. An increase in the 253 
diameter of the largest entry tear [Suppl. Figure 4], the diameter of the 254 
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descending thoracic aorta [Suppl. Figure 5] and the diameter of the descending 255 
thoracic aorta false lumen [Suppl. Figure 6] were all significantly associated with 256 
an increased hazard of aortic events during follow up. A one mm increase in both 257 
the size of the primary tear and the descending thoracic aorta was associated 258 
with a 7% increase in the hazard of an aortic event ((HR=1.07 (1.02-1.11), 259 
p=0.003) and (HR=1.07 (1.02-1.11), p=0.002), respectively) and a 5% increase 260 
for a 1mm increase in the descending thoracic aorta false lumen (HR=1.05 (1.01-261 
1.09), p=0.008).  262 
 263 
 264 
265 
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Discussion 266 
This study evaluates the outcomes of patients with type B aortic dissection 267 
treated endovascularly in the presence of complications and with best medical 268 
therapy in uncomplicated cases. The data at 1- and 5-years of follow-up 269 
demonstrate that there is no difference in all cause survival and aortic event-free 270 
survival between these two groups. Survival has traditionally been worse in 271 
patients with complicated compared with uncomplicated type B dissection, with 272 
survival figures in the region of 56.3-87% and 70.2-89% respectively at 5 273 
years.(7) Better outcomes can be achieved in complicated patients by early 274 
identification and active management of complications, a low rate of procedural 275 
mortality and morbidity and active management of patients during follow using 276 
blood pressure control, surveillance imaging and timely re-intervention when 277 
required.(1, 3, 8)  278 
 279 
The aim of thoracic endovascular treatment is to cover the proximal entry tear to 280 
direct aortic blood flow towards the true lumen, to induce false lumen 281 
thrombosis and positive aortic remodelling, with the intended benefit of 282 
improving survival. It is thought that early endovascular treatment is likely to 283 
result in the maximum amount of aortic remodelling, because the aorta still has 284 
plasticity, and therefore result in the best long-term outcomes. Thoracic 285 
endovascular repair in the acute setting is associated with a relatively high risk 286 
of retrograde type A aortic dissection.(9) In the context of life-threatening 287 
conditions such as rupture and visceral malperfusion this risk is considered 288 
acceptable. However in the absence of non-life threatening complications or 289 
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when considering prophylactic treatment of type B aortic dissection this risk 290 
must be carefully evaluated.  291 
 292 
The data in this manuscript suggest that thoracic endovascular aortic repair is 293 
not able to prevent all aortic events during follow up, which is one of the primary 294 
aims of this treatment. Data from the INSTEAD trial also shows at up to 52 295 
months, the mean follow-up in this series, a continued incidence of aortic events 296 
(4) and the consensus document also has similar findings.(4, 10, Nienaber, 2013 297 
#8090) Techniques other than thoracic endovascular repair are available and 298 
should be considered in the management of patients with chronic type B aortic 299 
dissection to try to augment the effect of endovascular repair. These include 300 
extension of the aortic endografting into the abdominal segment using branched 301 
and fenestrated devices, placement of endovascular coils and plugs (candy-plug) 302 
in the false lumen, occlusion of the false lumen by ballooning a stent graft in the 303 
true lumen to prevent retrograde flow (knickerbocker technique) and the 304 
STABILISE technique.(11-13) 305 
 306 
A more in depth evaluation of the anatomy in these patients demonstrates that 307 
patients in the group with complications treated endovascularly tended to have a 308 
larger primary entry tear, a larger starting aortic diameter, and a narrower true 309 
lumen compared with the group treated with medical treatment alone. Patients 310 
in the medically treated group tended to have a larger true compared with false 311 
lumen. These features suggest that the pressure in the false lumen of patients 312 
with complications on presentation may be greater than in the group treated 313 
medically. Following TEVAR thoracic but not abdominal aortic remodelling was 314 
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seen, which is consistent with the results of other series.(14) Approximately one 315 
third of patients in the endovascular group did not have false lumen thrombosis 316 
in the thoracic aorta at 2 years, and this led to a progressive increase in thoracic 317 
aortic diameter during follow-up. This residual flow in the false lumen in these 318 
patients may have influenced the incidence of aortic events during follow-319 
up.(15) The long follow-up in this series allows a particular evaluation of false 320 
lumen thrombosis in type B aortic dissection the over time.  321 
 322 
Uncomplicated patients with type B aortic dissection typically follow a varied 323 
course following presentation. Some centres now advocate high frequency serial 324 
imaging (~3 CT angiograms) in the first ten days following presentation to try to 325 
identify patients early that are likely to undergo rapid development of aortic 326 
complications. In this series we have shown that anatomic features such as a 327 
large proximal entry tear, a large descending thoracic aortic diameter and a large 328 
diameter of the descending thoracic aortic false lumen on presentation are 329 
related to an increased hazard of experiencing an aortic event during follow-up. 330 
Taller patients were also more likely to experience an aortic event during follow 331 
up and may represent a group with undiagnosed connective tissue disease.(16) 332 
The effect of height on outcomes was significant, with a 10cm increase in height 333 
resulting in a 48% increase in the hazard of experiencing an aortic event during 334 
follow up. Blood pressure control was shown to have a significant effect on all-335 
cause survival, with more active management related to better outcomes.  336 
 337 
The International Registry of Aortic Dissection (IRAD) contains data collected 338 
from centres across the world and represents a unique resource to study the 339 
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diagnosis and management of patients with aortic dissection.(17) One of the 340 
limitations of the registry however is the heterogeneity of the data, which 341 
reflects the local clinical management of patients and local CT image 342 
interpretation in each of the centres. One of the strengths of the series described 343 
in the current manuscript is that patients were treated in a single centre, with a 344 
standardised procedure for clinical management and image interpretation. 345 
During the course of the study there was an increase in the level of clinical and 346 
surgical experience and this is one of the limitations of this study, also data on re-347 
intervention and stent graft type was not collected. The image analysis was 348 
limited in that inter- and intra-observer reproducibility was not specifically 349 
performed and thrombosis was assumed to be present when contrast in the false 350 
lumen was absent; standard clinical acquisition protocols were used but these 351 
can over-represent the amount of thrombosis if low-flow states are present.  352 
 353 
In conclusion, active management of patients with type B aortic dissection 354 
results in good long-term survival despite presenting features that have 355 
traditionally been associated with adverse outcomes. All patients require close 356 
lifetime surveillance as aortic events, even after endografting, continue to occur 357 
during follow-up.  358 
359 
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Tables 422 
 All Endovascular 
treatment 
 
Medical 
treatment 
only 
p-
value 
Total 136 64 72  
Age, mean(sd) 61.7(13.2) 58.5(12.7) 64.5(13.1) 0.008 
Male sex, % 77.2 79.7 75.0 0.515 
Height (cm), mean(sd) 173.5(9.7) 174.6(8.9) 172.6(10.3) 0.264 
Hypertension, % 71.3 75.0 68.1 0.371 
Diabetes, % 9.6 9.9 9.4 0.924 
Dyslipidaemia, % 25.0 17.2 31.9 0.047 
BMI, median(IQR) 27(24.2-
31.0) 
27.0(24.0-
31.4) 
26.9(24.4-
29.7) 
0.945 
Coronary artery disease, 
% 
5.9 4.7 7.0 0.721 
Co-existing AAA, % 9.6 10.9 8.5 0.625 
Previously treated AAA, % 4.4 0 8.5 0.029 
Renal insufficiency, % 0 0 0  
Connective tissue disease, 
% 
5.9 9.4 2.8 0.149 
Family history of Marfan, 
% 
3.7 4.7 2.8 0.668 
 423 
Table 1.  424 
Patient characteristics 425 
  426 
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 All Endovascular 
treatment 
Medical 
treatment 
only 
p-value 
Presentation     
Maximum aortic diameter, median(IQR) 38(35-43) 41(36-45) 37(34-40) 0.003 
Dissection involving thoracic and abdominal aorta, % 87.2 93.0 81.7 0.096 
Total diameter of the thoracic aorta, median(IQR) 37(34-42) 39(34-42) 36(32.5-38) 0.006 
True lumen diameter in the thoracic aorta, median(IQR) 18(14-23) 18(15-24) 19.5(12.5-23) 0.900 
False lumen diameter in the thoracic aorta, median(IQR) 18(12-26) 20(14-28) 17(10-23) 0.060 
False lumen status, %     
   Patent 52.6 59.7 45.8 0.105 
   Partially thrombosed 38.8 36.8 40.7  
   Completely thrombosed 8.6 3.5 13.6  
     
2 years     
Maximum aortic diameter, median(IQR) 40.5(36-44.5) 42(38-47) 39(35-42) 0.088 
Total diameter of the thoracic aorta, median(IQR) 40(36-43) 41(36-44) 38(35-41) 0.067 
True lumen diameter in the thoracic aorta, median(IQR) 25(15-30) 25.5(16-30) 21(13-28) 0.180 
False lumen diameter in the thoracic aorta, median(IQR) 18(8-27) 18.5(8-28) 18(8-26) 0.665 
False lumen status, %     
   Patent 24.3 31.7 13.8 0.184 
   Partially thrombosed 41.4 34.2 51.7  
   Completely thrombosed 34.3 34.2 34.5  
     
5 years     
Maximum aortic diameter, median(IQR) 40(37-47) 42(38-48) 37.5(33-41.5) 0.045 
Total diameter of the thoracic aorta, median(IQR) 40.5(36-44.5) 42(38-47) 39(35-42) 0.088 
True lumen diameter in the thoracic aorta, median(IQR) 23(16-31) 20(16-32) 28(18-30) 0.600 
False lumen diameter in the thoracic aorta, median(IQR) 21(8.5-28) 23(12-28) 14(4-34) 0.316 
False lumen status, %     
   Patent 28.6 39.4 6.3 0.049 
   Partially thrombosed 38.8 33.3 50.0  
   Completely thrombosed 32.7 27.3 43.8  
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Table 2. 429 
Anatomical features of the patient cohort 430 
431 
 22 
Figure legends 432 
Figure 1: Kaplan Meier estimate demonstrating 94.4% and 75.5% cumulative 433 
overall survival at one and five years respectively 434 
 435 
Figure 2: The aortic event-free survival at one year and at five years was 75.5% 436 
and 58.0% respectively  437 
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